Long-term effects of weight-reducing drugs in people with hypertension - PubMed

4 hours ago

Weight-reducing drugs like orlistat, phentermine/topiramate, and naltrexone/bupropion have uncertain effects on all-cause mortality and cardiovascular morbidity in hypertensive adults, based on very low-certainty evidence.
Orlistat probably increases serious adverse events, while phentermine/topiramate and naltrexone/bupropion likely raise overall adverse events, though data on serious adverse events for these drugs is uncertain.
Recent drugs semaglutide and tirzepatide were included in trials, but no results were reported for critical outcomes like mortality or cardiovascular morbidity.
The review highlights insufficient evidence to conclude that pharmacological weight loss reduces mortality or cardiovascular risk in hypertension, calling for more trials and separate data for hypertensive participants.

Hasty Briefsbeta